Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Advanced Solid Tumor 12Solid Tumor 5Nasopharyngeal Carcinoma 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Sarcoma 2Recurrence 2Neoplasms 2Locally Advanced or Metastatic Solid Tumors 2Liposarcoma 2Advanced Solid Tumors 2Advanced Lung Cancer 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor, Adult 1Solid Cancer 1Small Cell Lung Carcinoma 1Pyloric Stenosis, Hypertrophic 1Pancreatic Neoplasms 1Pancreatic Cancer Metastatic 1PD-1 1Ovarian Neoplasms 1Meningeal Carcinomatosis 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Leiomyosarcoma 1

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Cancer × toripalimab × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡